ClinicalTrials.gg
CompletedNCT00221000RA-1Updated Oct 19, 2016

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Rheumatoid Arthritis

A Phase 2 interventional study of Methoxsalen and Extracorporeal Photopheresis in Rheumatoid Arthritis, sponsored by Mallinckrodt. Completed at 32 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2016-10-19.

Sponsored by Mallinckrodt · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
86
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 975 studies in Arthritis, Rheumatoid with a site in United States — 82 open to participants now, 122 under way, 7 of them phase 3. Arthritis, Rheumatoid · United States.

Enrollment
446th of 771
86 · median 120
Started
2003
with 21 others
Phase 2
215 of 975
12 open now
Registered
81st of 975
by date

Among the 975 studies in Arthritis, Rheumatoid with a site in United States, this one is the 446th largest by enrollment of the 771 interventional ones that give a count, is one of 22 that started in 2003, is one of 215 in phase 2, and was the 81st registered.

Arthritis, Rheumatoid

3,335 studies on the registry are indexed under Arthritis, Rheumatoid; 445 are open to participants now.

Browse Arthritis, Rheumatoid studies →

Open to participants now

82 of the 975 studies in Arthritis, Rheumatoid with a site in United States are open now. Recruiting first, the newest first:

77 more — sign in →

All 82 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 294 Arthritis, Rheumatoid studies recruiting now, 151 (51%) set no upper age limit and 109 (37%) stop at 75 or younger; 15 take children under 18; 36 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 975 studies in Arthritis, Rheumatoid with a site in United States, or all of them as a file.
02

Study summary

Rheumatoid arthritis (RA) is a systemic autoimmune inflammatory disorder that can cause substantial pain and joint tenderness, significant joint damage, and serious disability. The treatment goals are minimization of the signs and symptoms of the disease, and the reduction of irreversible joint damage.

As the understanding of the pathophysiological mechanisms underlying RA is elucidated, the opportunity to target specific inflammatory processes with new therapies has improved. Rheumatoid arthritis is a T cell-mediated autoimmune disease and there are various therapies, including newer experimental therapies, which target either the activation of T cells or the neutralization of their effector mechanisms. These newer therapies have shown benefit in human and animal models of RA. Extracorporeal photoimmune therapy (ECP) has been shown to be safe and effective in the palliative treatment of the skin manifestations of cutaneous T cell lymphoma. Experimental studies have also demonstrated activity of ECP treatment in several T cell mediated diseases including graft versus-host disease, rejection after organ transplantation, and selected autoimmune diseases.

This study will evaluate a cell-based therapy (ECP) in patients who have an inadequate response to disease-modifying antirheumatic drugs (DMARDs) and biological agents to determine if ECP treatment can reduce the signs and symptoms of RA in this refractory patient population.

03

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Rheumatoid Arthritis
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients must have a history of RA per the ACR criteria for the classification of RA.
  • Patients must have moderately to severely active RA.

Moderately to severely active RA patients are defined as those patients meeting the following classification criteria, upon review by a physician, during screening: At least nine tender joints; At least six swollen joints;

PLUS (at least one of the following):

Morning stiffness, lasting greater than or equal to 45 minutes; Erythrocyte Sedimentation Rate greater than or equal to 28 mm/hour (ESR, to be evaluated at a local laboratory) or C reactive protein (CRP) greater than or equal to 15 mg/dL (to be evaluated at a central laboratory).

  • Patients must have an inadequate response and continue to have moderately to severely active disease while on current or previous treatment with at least one agent from both of the following groups: methotrexate (greater than or equal to 15 mg/week, or maximum tolerated dose) or leflunomide (20 mg/day, or maximum tolerated dose) for at least 12 weeks prior to screening; etanercept ( greater than or equal to 25 mg/2 x week SC, or maximum tolerated dose) for at least 12 weeks prior to screening, infliximab (greater than or equal to 3 mg/kg IV, or maximum tolerated dose) for at least 14 weeks duration prior to screening, or adalimumab (greater than or equal to 40 mg SC every 2 weeks, or maximum tolerated dose) for at least 12 weeks prior to screening.

Note: In individual cases or in a country where access to anti TNF agents is limited or anti TNF agents are unavailable, the Investigator should document the reason for lack of availability of this treatment. Those patients who have not been treated with an anti-TNF agent would still be eligible for the study if they have failed treatment with at least two additional DMARDs, besides MTX and/or leflunomide. All patients may have also failed treatment with other biological agents or a protein A column.

  • Patients who are not on oral . OR Patients who have been on a stable dose of oral corticosteroids at a prednisone equivalent dosage greater than or equal to 15 mg/day for at least 4 weeks prior to screening.
  • Patients must have a count greater than or equal to 100,000/cmm.
  • Female patients must be one of the following: , surgically incapable of bearing children, practicing an acceptable method of (acceptable methods may include hormonal contraceptives, intrauterine device, and spermicide and barrier). Abstinence or partner/spouse sterility may also qualify at the Investigator's discretion. If a female patient is of , she must have a negative urine pregnancy test at screening.
  • Patients must be able and willing to comply with all study procedures.
  • Patients must be willing to sign an ICF.
  • Patients must be greater than or equal to 18 years of age.
  • Patients must have a body weight greater than or equal to 40 kg (88 lb).

Exclusion criteria

Exclusion Criteria:

  • Patients who have a form of arthritis or arthropathy, other than RA, or any current inflammatory condition that might confound the assessments (e.g., other connective tissue diseases or Lyme disease).
  • Patients who have been enrolled in any therapy study for the treatment of RA within 4 weeks prior to the start of the Treatment Period, or patients who are scheduled to receive investigational therapies or a plasma based apheresis procedure (e.g., a protein A column) for the treatment of RA during the course of the study.
  • Patients unable to tolerate the extracorporeal volume shifts associated with ECP treatment due to the presence of any of the following conditions: uncompensated congestive heart failure, pulmonary edema, severe , severe asthma, renal failure, or hepatic failure.
  • Patients with a poor tolerability of venipuncture or a lack of adequate venous access for required treatments and blood sampling.

Note: Every attempt should be made to enroll patients who have adequate peripheral venous access.

  • Patients who have a known or allergy to psoralen (methoxsalen).
  • Patients who have a known hypersensitivity or allergy to both heparin and citrate products.
  • Patients who are taking any of the following permitted DMARDs and biological agents and have not been on a stable dose for the specific indicated periods of time prior to screening: MTX for at least 8 weeks; leflunomide for at least 8 weeks; infliximab for at least 14 weeks; etanercept for at least 12 weeks; adalimumab for at least 12 weeks.
  • Patients who are taking any of the following permitted medications and have not been on a stable dose for at least 4 weeks prior to screening: NSAIDs; anakinra; hydroxychloroquine; chloroquine; sulfasalazine; D-penicillamine; gold salts; azathioprine; oral (greater than or equal to 15 mg/day, prednisone equivalent dose).
  • Patients whom the Investigator believes cannot be maintained on stable doses of permitted concomitant RA medications throughout the Treatment Period.
  • Patients who are taking any of the following prohibited medications: cyclophosphamide; chlorambucil; intramuscular (IM) or intravenous (IV) corticosteroid injection(s), within 4 weeks of screening; intra-articular corticosteroid injection(s) > 60 mg prednisone equivalent total dose, within 4 weeks of screening.
  • Patients who have any known malignant disease (other than basal cell carcinoma) currently or within the last 5 years.
  • Patients who have a pre-existing blood dyscrasia such as bone marrow hypoplasia, leukopenia, thrombocytopenia, significant anemia, or a coagulation disorder.
  • Patients with a persistent or severe infection within 12 weeks of screening.
  • Patients with a history of drug or alcohol abuse within 12 weeks of screening.
  • Patients with impaired hepatic function at screening as shown by abnormal liver function tests (LFT; i.e., [AST] or alanine transaminase [ALT] levels > 2 x the [ULN]).
  • Women who are pregnant or lactating.
Terms in these criteria, in plain language(10)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
86 participants (actual)

Interventions

06

What researchers measure

Primary outcomes

  1. ACR 20

    At least a 20% improvement of ACR 20 from baseline

    Time frame: week 24 and week 28

Secondary outcomes

  1. ACR 50

    Improvement of at least 50% from baseline on ACR 50

    Time frame: week 24 and week 28

07

Study locations

32 sites
  • Carroll County Arthritis and Osteoporosis Center
    Westminister, Maryland, United States
  • Clinical Pharmacology Study Group
    Worchester, Massachusetts, United States
  • Morristown Memorial Hospital
    Morristown, New Jersey, United States
  • AAIR Research Center
    Rochester, New York, United States
  • Carolina Arthritis Associates
    Wilmington, North Carolina, United States
  • Rheumatic Disease Associates
    Willow Grove, Pennsylvania, United States
  • Rheumatology Associates
    Providence, Rhode Island, United States
  • UT Southwestern Medical Center
    Dallas, Texas, United States
  • Arthritis and Osteoporosis Center of South Texas
    San Antonio, Texas, United States
  • Benaroya Research Institute at Virginia Mason
    Seattle, Washington, United States
  • Royal Brisbane Hospital
    Herston, Australia
  • General Hospital of Vienna
    Vienna, Austria
  • Hospital Brugmann
    Bruxelles, Belgium
  • Limburgs Universitair Centrum
    Diepenbeek, Belgium
  • Rebecca MacDonald Centre for Arthritis
    Toronto, Ontario, Canada
  • CHRU de Lille
    Lille, France
  • Hopital Edouard Herriot
    Lyon, France
  • Franz von Prummer Klinik
    Bad Bruckenau, Germany
  • University of Charite Clinic for Rheumatology and Immunology
    Berlin, Germany
  • Medizinische Klinik III
    Erlangen, Germany
  • Abt. Rheumatologie und Klinische Immunologie
    Hamburg, Germany
  • Klinikum der Universitat zu Koln
    Koln, Germany
  • Westfalische wilhelms-universitat Munster
    Munster, Germany
  • Medizinische Klinik des Evangelischen Kranken
    Oldenburg, Germany
  • Universita degli Studi di Firenze
    Firenze, Italy
  • Universita de Genova - Ospedale S. Martino
    Genova, Italy
  • University of Siena-Italy
    Siena, Italy
  • OPD- Hospital Civil "Dr. Jaun I. Menchaca"
    Guadalajara, Jalisco, Mexico
  • Reumatologicka ambulancia, Polinika
    Bratislava, Slovakia
  • South African National Blood Service
    Bloemfontein, South Africa
  • Christian Barnard Mermorial Hospital
    Cape Town, South Africa
  • D6 Rheumatology Clinic and E5 Hematology Unit
    Cape Town, South Africa
08

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Aug 2003, a primary completion of Oct 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2005
First posted
Sep 22, 2005
Start
Aug 2003
Primary completionActual
Oct 2006
CompletionActual
Nov 2006
Last update
Oct 19, 2016
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 19, 2016, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00221000
Lead sponsor
Mallinckrodt
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Aug 2003
Primary completion
Oct 2006
Completion
Nov 2006
Last update
Oct 19, 2016

Study contacts

EDWARD KEYSTONE, MD
principal investigator · Rebecca MacDonald Centre for Arthritis

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Methoxsalen

Start the discussion